10062071Size Matters: Determination of critical control parameters for assay performanceClosedCollaborative R&DInnovate UKOver 250 million antibiotic prescriptions are issued annually; nearly half are done blindly. Incorrect prescriptions lead to drug resistant infections, which kill 1.2 million people annually and will kill more people than cancer by 2050\. FluoretiQ's mission is to provide clinicians with rapid tests to make their first antibiotic prescription, the right prescription. Our rapid testing platforms (NANOPLEX & SCFI) reduce diagnosis and antibiotic selection turnaround time from days to minutes, making the first prescription, the right prescription. NANOPLEX is an advanced latex agglutination test that uses glycan probes and machine learning to identify and quantify bacteria in 15 mins rather than 2 days, with over 90% accuracy. The first of our products is (codenamed) P5; a 15-minute diagnostic test from the NANOPLEX family. P5 addresses the unmet need for accurate point of care testing of urinary tract infections (UTIs) that affects 150 million people globally each year. P5 will provide a clear treat/do not treat evidence from the first consultation. P5 identifies the most important uropathogens. For this project, FluoretiQ will collaborate with experts from the National Physics Laboratory (NPL) and Newton Gateway to Mathematics (Newton) to create a mathematical model of the NANOPLEX assay which will help identify additional control parameters for maintaining performance of the test.